{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:26:32Z","timestamp":1778613992689,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.steroids.2021.108930","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T02:26:22Z","timestamp":1634005582000},"page":"108930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adrenocorticotropic hormone: An expansion of our current understanding of the treatment for nephrotic syndrome"],"prefix":"10.1016","volume":"176","author":[{"given":"Dongxu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9384","key":"10.1016\/j.steroids.2021.108930_b0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet (London, England)."},{"issue":"6","key":"10.1016\/j.steroids.2021.108930_b0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.ajkd.2003.08.010","article-title":"Is there really an increase in non-minimal change nephrotic syndrome in children?","volume":"42","author":"Filler","year":"2003","journal-title":"Am. J. Kidney Dis."},{"issue":"12","key":"10.1016\/j.steroids.2021.108930_b0015","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s004670100021","article-title":"Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK","volume":"16","author":"McKinney","year":"2001","journal-title":"Pediatric Nephrol. (Berlin, Germany)"},{"key":"10.1016\/j.steroids.2021.108930_b0020","unstructured":"Nephrology group, Chinese academy of pediatrics. Evidence based guidelines for the diagnosis and treatment of steroid resistant nephrotic syndrome (2016). Chin. J. Pediatrics (2017) 55: 805-809 (Chinese)."},{"key":"10.1016\/j.steroids.2021.108930_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/2597079","article-title":"ACTH treatment for management of nephrotic syndrome: a systematic review and reappraisal","volume":"2020","author":"Chakraborty","year":"2020","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.steroids.2021.108930_b0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1749-6632.2009.04434.x","article-title":"Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer: a thirty-year retrospective","volume":"1163","author":"Dores","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.steroids.2021.108930_b0035","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1210\/er.2006-0034","article-title":"Studies on the physiological functions of the melanocortin system","volume":"27","author":"Cone","year":"2006","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.steroids.2021.108930_b0040","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/1389450033490858","article-title":"Melanocortins and their receptors and antagonists","volume":"4","author":"Voisey","year":"2003","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.steroids.2021.108930_b0045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/PL00000868","article-title":"Melanocortin receptors: their functions and regulation by physiological agonists and antagonists","volume":"58","author":"Abdel-Malek","year":"2001","journal-title":"Cell. Mol. Life Sci.: CMLS"},{"issue":"2","key":"10.1016\/j.steroids.2021.108930_b0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","article-title":"Leveraging melanocortin pathways to treat glomerular diseases","volume":"21","author":"Gong","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"2","key":"10.1016\/j.steroids.2021.108930_b0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"issue":"5897","key":"10.1016\/j.steroids.2021.108930_b0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/301255a0","article-title":"Evidence that the insulin secretagogue, beta-cell-tropin, is ACTH22-39","volume":"301","author":"Beloff-Chain","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2021.108930_b0065","first-page":"548A","article-title":"ACTH (Acthar Gel) prevents proteinuria and renal injury in the remnant kidney: evidence for direct podocyte protection","volume":"21","author":"Gong","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.steroids.2021.108930_b0070","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1681\/ASN.2009101025","article-title":"Melanocortin 1 receptor agonists reduce proteinuria","volume":"21","author":"Lindskog","year":"2010","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0075","doi-asserted-by":"crossref","first-page":"15731","DOI":"10.1038\/s41598-018-34004-7","article-title":"Amplification of the melanocortin-1 receptor in nephrotic syndrome identifies a target for podocyte cytoskeleton stabilization","volume":"8","author":"Bergwall","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/srep27589","article-title":"MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy","volume":"6","author":"Qiao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2021.108930_b0085","doi-asserted-by":"crossref","unstructured":"Y. Qiao, P. Wang, M. Chang, B. Chen, Y. Ge, D. Malhotra, et al. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling. Clin. Sci. (London, England: 1979). 2020;134(7):695-710.","DOI":"10.1042\/CS20200016"},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.56.1.1","article-title":"Targeting melanocortin receptors as a novel strategy to control inflammation","volume":"56","author":"Catania","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.steroids.2021.108930_b0095","doi-asserted-by":"crossref","unstructured":"Cooper A, Robinson S, Pickard C, Jackson C, Friedmann P, Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J. Immunol. (Baltimore, Md : 1950). 2005;175(7):4806-13.","DOI":"10.4049\/jimmunol.175.7.4806"},{"issue":"3","key":"10.1016\/j.steroids.2021.108930_b0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-3083.2005.01565.x","article-title":"Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytes","volume":"61","author":"Andersen","year":"2005","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2008.94","article-title":"Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats","volume":"74","author":"Yeboah","year":"2008","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.steroids.2021.108930_b0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cardiores.2004.03.029","article-title":"Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway","volume":"63","author":"Guarini","year":"2004","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40620-016-0308-3","article-title":"Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance","volume":"30","author":"Lieberman","year":"2017","journal-title":"J. Nephrol."},{"key":"10.1016\/j.steroids.2021.108930_b0120","unstructured":"Nephrology group, Chinese academy of pediatrics. Evidence based guidelines for the diagnosis and treatment of steroid sensitive, relapsing\/dependent nephrotic syndrome in children (2016). Chin. J. Pediatrics. (2017)55:729-734. (in Chinese)."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0125","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2169","article-title":"Acquired resistance to corticotropin therapy in nephrotic syndrome: role of De Novo neutralizing antibody","volume":"140","author":"Wang","year":"2017","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.steroids.2021.108930_b0130","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2215\/CJN.06890618","article-title":"Adrenocorticotropic hormone for childhood nephrotic syndrome: the ATLANTIS randomized trial","volume":"13","author":"Wang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"key":"10.1016\/j.steroids.2021.108930_b0135","first-page":"637","article-title":"Clinical observation of the treatment of adrenocorticotropic hormone in children with frequently relapsing nephritic syndrome","volume":"35","author":"Han","year":"2020","journal-title":"Chin. J. Appl. Clin. Pediatr."},{"issue":"4","key":"10.1016\/j.steroids.2021.108930_b0140","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1046\/j.1523-1755.1999.00675.x","article-title":"Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy","volume":"56","author":"Berg","year":"1999","journal-title":"Kidney Int.."},{"issue":"2","key":"10.1016\/j.steroids.2021.108930_b0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am. J. Kidney Dis."},{"issue":"11","key":"10.1016\/j.steroids.2021.108930_b0150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","article-title":"Pharmacological treatment of primary membranous nephropathy in 2016","volume":"9","author":"van de Logt","year":"2016","journal-title":"Exp. Rev. Clin. Pharmacol.."},{"issue":"8","key":"10.1016\/j.steroids.2021.108930_b0155","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.steroids.2021.108930_b0160","doi-asserted-by":"crossref","first-page":"e0142033","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study","volume":"10","author":"van de Logt","year":"2015","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.steroids.2021.108930_b0165","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel","volume":"8","author":"Hogan","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"issue":"8","key":"10.1016\/j.steroids.2021.108930_b0170","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/TP.0000000000002320","article-title":"ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation","volume":"103","author":"Alhamad","year":"2019","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.steroids.2021.108930_b0180","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.transproceed.2019.04.052","article-title":"Adrenocorticotropic hormone in the treatment of focal segmental glomerulosclerosis following kidney transplantation","volume":"51","author":"Grafals","year":"2019","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.steroids.2021.108930_b0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan","year":"2016","journal-title":"BMC Nephrol."},{"issue":"5","key":"10.1016\/j.steroids.2021.108930_b0190","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ekir.2017.05.015","article-title":"Safety and efficacy of combination ACTHar gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy","volume":"2","author":"Tumlin","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.steroids.2021.108930_b0195","unstructured":"J. Gettig, J. Cummings, K. Matuszewski, H.p. Acthar gel and cosyntropin review: clinical and financial implications. P & T : a peer-reviewed journal for formulary management. 2009;34(5):250-7."},{"issue":"9","key":"10.1016\/j.steroids.2021.108930_b0200","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/jps.10442","article-title":"Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification","volume":"92","author":"Wan","year":"2003","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0303-7207(80)90092-1","article-title":"Evidence that glycosylation of pro-opiocortin and ACTH influences their proteolysis by trypsin and blood proteases","volume":"20","author":"Loh","year":"1980","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2021.108930_b0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/IJNRD.S74349","article-title":"Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study","volume":"8","author":"Lorusso","year":"2015","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"issue":"1","key":"10.1016\/j.steroids.2021.108930_b0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0008-6363(98)00230-2","article-title":"The role of corticosteriods in the regulation of vascular tone","volume":"41","author":"Ullian","year":"1999","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.steroids.2021.108930_b0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.mnh.0000133976.32559.b0","article-title":"Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension","volume":"13","author":"Frey","year":"2004","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.steroids.2021.108930_b0225","article-title":"Central precocious puberty as a complication of therapy with adrenocorticotropin (ACTH) and an aromatase inhibitor for refractory nephrotic syndrome","volume":"2019","author":"Agrawal","year":"2019","journal-title":"Case Rep. Pediatr."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X21001422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X21001422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:08:13Z","timestamp":1758535693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X21001422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"alternative-id":["S0039128X21001422"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2021.108930","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adrenocorticotropic hormone: An expansion of our current understanding of the treatment for nephrotic syndrome","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2021.108930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108930"}}